Use of transglutaminase inhibitor for the treatment of scar tissue
CA 2132416 C · Owner: Bowness, John Michael · Inventors: Bowness, John Michael; Dolynchuk, Kenneth Nicholas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the therapeutic treatment of hypertrophic scar tissue within a composition comprising a non-toxic transglutaminase inhibitor, such as putrescine or a pharmaceutically , acceptable acid addition salt thereof and a pharmaceutically, acceptable carrier or diluent. A successful method for treating hypertrophic scar tissue with such compositions, is also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 23, 1992 and granted March 6, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 23, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 23, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.